Clearside Biomedical (CLSD) Scheduled to Post Earnings on Tuesday

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) is set to post its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Clearside Biomedical to post earnings of ($0.14) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.25 million. During the same period in the previous year, the firm earned ($0.15) EPS. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clearside Biomedical Trading Up 3.9 %

CLSD stock traded up $0.04 during midday trading on Tuesday, reaching $1.07. 268,254 shares of the company's stock traded hands, compared to its average volume of 405,547. Clearside Biomedical has a 52-week low of $0.76 and a 52-week high of $2.12. The stock has a market cap of $79.96 million, a P/E ratio of -2.14 and a beta of 2.33. The stock's 50-day moving average is $1.18 and its 200 day moving average is $1.20.

Insider Transactions at Clearside Biomedical

In other Clearside Biomedical news, insider Ngai Hang Victor Chong bought 36,500 shares of the firm's stock in a transaction on Friday, November 1st. The stock was bought at an average cost of $1.00 per share, with a total value of $36,500.00. Following the completion of the transaction, the insider now directly owns 100,000 shares of the company's stock, valued at approximately $100,000. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CLSD shares. StockNews.com raised shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a research note on Friday, October 18th. Needham & Company LLC raised their price target on shares of Clearside Biomedical from $4.00 to $6.00 and gave the stock a "buy" rating in a report on Thursday, October 10th. Chardan Capital reissued a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research report on Monday, October 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Clearside Biomedical in a research report on Tuesday, August 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Clearside Biomedical has a consensus rating of "Moderate Buy" and an average target price of $5.17.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.